<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336985</url>
  </required_header>
  <id_info>
    <org_study_id>110131</org_study_id>
    <secondary_id>11-CC-0131</secondary_id>
    <nct_id>NCT01336985</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads</brief_title>
  <official_title>Phase Ib Study of the Safety and Pharmacokinetics of Chemoembolization With Irinotecan-Eluting Beads for the Treatment of Hepatic Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

        -  Cancers in other parts of the body often spread to the liver, developing tumors which in
           many instances cannot be removed with surgery. Liver chemoembolization is a treatment
           that is routinely performed to control liver tumors in those who cannot have surgery. It
           has been shown to prolong survival, but does not cure the cancer. During
           chemoembolization very tiny beads (drug-eluting beads, or DEB) containing chemotherapy
           drugs (usually doxorubicin) are administered directly into the blood vessels of a liver
           tumor. The drug within the beads is then released into the tumor whilethe beads
           temporarily interrupt the tumor s blood supply.

        -  Irinotecan, a drug commonly given intravenously to treat colon cancer, has been given in
           chemoembolization procedures in four other studies that have shown that the treatment is
           generally well tolerated. Researchers are interested in determining whether giving the
           drug irinotecan directly into the liver using drug-eluting beads is not only well
           tolerated but also provides a larger dose directly to the tumor as determined by tumor
           and normal liver tissue biopsies. The liver biopsies are an optional portion of the
           study.

      Objectives:

      - To evaluate the safety and effectiveness of chemoembolization with irinotecan for tumors
      caused by cancer that has spread to the liver.

      Eligibility:

      - Individuals at least 18 years of age who have melanoma, colon, or another intra-abdominal
      cancer that has spread to the liver.

      Design:

        -  Participants will be screened with a physical examination, medical history, blood tests,
           tumor imaging studies, and liver biopsies.

        -  Participants will receive up to 3 DEB chemoembolization treatments about 6 weeks apart.

        -  After two treatments, participants will have imaging studies to see if the tumors have
           shrunk, and those whose tumors have shrunk may have a third treatment.

        -  Multiple liver biopsies may be performed and blood samples will be taken to determine
           how much drug is in the tumor and the circulation, and to see how the tumor reacts to
           the drug.

        -  Participants will return for followup visits for up to 1 year....
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Clinical evidence suggests that hepatic chemoembolization may prolong survival in
           patients with hepatic metastases.

        -  Early studies have indicated that chemoembolization using irinotecan drug eluting beads
           may be more effective in treating hepatic metastases from colon or melanoma primary
           tumors.

      Objectives:

        -  Primary Objective:

           --To determine the safety of hepatic chemoembolization with drug-eluting beads
           containing 100mg of irinotecan

        -  Secondary Objectives:

             -  To determine the serum pharmacokinetics and tumor tissue concentrations achieved
                following hepatic chemoembolization with irinotecan-eluting beads

      Eligibility:

        -  Patients &gt; 18 years of age with pathologically proven hepatic metastases from the
           gastrointestinal tract, or melanoma with unresectable hepatic lesions.

        -  Patients whose extent of hepatic metastases represents &lt;60% of total liver volume AND
           whose extrahepatic metastatic disease is determined to be minimal

        -  Patients must be ECOG performance status of less than or equal to 2 and a life
           expectancy of more than 3 months.

        -  Patients must have adequate organ function.

        -  Patients must not have had chemotherapy, radiation therapy, or biological therapy for at
           least 4 weeks prior to starting study treatments.

        -  Patients are not to receive conventional chemotherapy or therapeutic monoclonal
           antibodies while on study.

        -  Patients must not have an acute, critical illness.

      Design:

        -  A Phase Ib trial in which patients undergo hepatic chemoembolization with drug-eluting
           beads containing 100mg irinotecan.

        -  Up to 15 patients will be enrolled over 1 year to accrue 10 evaluable patients.

        -  Patients will undergo up to 3 chemoembolizations.

        -  Following chemoembolization, patients will have serial serum pharmacokinetic samples
           drawn and tumor biopsies in order to measure serum and tumor tissue concentrations of
           irinotecan

        -  Patients will be followed for one year after completion of the last treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 28, 2011</start_date>
  <completion_date type="Actual">March 28, 2011</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of hepatic chemoembolization with drug-eluting beads containing 100mg of irinotecan</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the serum pharmacokinetics and tumor tissue concentrations achieved following hepatic chemoembolization with irinotecan-eluting beads</measure>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Neoplasm Metastases</condition>
  <condition>Melanoma</condition>
  <condition>Colorectal Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chemoembolization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-Eluting Beads</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Patients with pathologically proven hepatic-dominant metastases from abdominal or
             gastrointestinal tract primary malignancy or melanoma where the life limiting
             component of the disease is hepatic metastasis

          -  Patients must have unresectable hepatic lesions or must be unable or unwilling to
             undergo surgical resection. Patients may have undergone prior wedge resection of the
             liver for metastatic disease

          -  All patients must be refractory to or intolerant of approved standard systemic
             therapy.

        Specifically:

          -  Patients with metastatic colorectal must have received 5-FU and leucovorin in
             combination with either oxaliplatin and/or irinotecan, since level 1 evidence support
             increase survival with these regimens, compared to 5-FU and leucovorin alone.

          -  Patients with melanoma must have received IL-2 or other immunotherapy options (such as
             ipilimumab or adoptive cell therapy) that have been reported to have efficacy.

               -  Patients with extrahepatic metastases or an unresected primary lesion will be
                  considered eligible if the extrahepatic disease is minimal

               -  Extent of hepatic metastases is &lt;60% of total hepatic volume.

               -  Patients must have at least one lesion that can be readily biopsied (at least
                  10mm diameter)

               -  ECOG performance status less than or equal to 2

               -  Life expectancy &gt; 3 months

               -  At least 18 years of age

               -  Age &lt; 85 years

               -  Patients must have had no chemotherapy, radiotherapy, or biologic therapy for
                  their malignancy for at least 4 weeks (or until response can be adequately
                  assessed) prior to treatment and must have recovered from all clinically
                  significant side effects of therapeutic and diagnostic interventions. Anti-VEGF
                  agents (eg, Avastin) may not be administered less than 4 weeks prior to DEB-TACE
                  treatment.

               -  Patients are not to receive conventional chemotherapy or therapeutic monoclonal
                  antibodies while receiving protocol treatment

               -  Hematology:

          -  Absolute neutrophil count greater than 1500/mm(3) without the support of Filgrastim.

          -  Platelet count greater than 75,000/mm(3).

          -  Hemoglobin greater than 8.0 g/dl.

             -Chemistry:

          -  Serum ALT/AST less than or equal to 3 times the upper limit of normal.

          -  Serum creatinine less than or equal to 2.0 mg/dl unless the measured creatinine
             clearance is greater than 60 mL/min

          -  Total bilirubin less than or equal to 2 mg/dl.

          -  INR &lt;1.5

          -  PTT less than or equal to 1.3 times control unless a mixing study confirms the
             presence of a lupus anticoagulant as the cause for the prolonged PTT.

               -  Screening electrocardiogram is normal with QTc less than or equal to 480msec).

        EXCLUSION CRITERIA:

          -  Significant cardiac or pulmonary insufficiency as evidenced by

               -  history of congestive heart failure with an LVEF &lt; 40%

               -  history of COPD or other chronic pulmonary disease with PFT s indicating an FEV1
                  less than 30% or a DLCO less than 40% predicted for age

          -  Portal Vein Occlusion or other contraindications to chemoembolization

          -  Inflammatory bowel disease

          -  Prior chemoembolization therapy

          -  Prior precutaneous hepatic perfusion therapy

          -  Prior selective internal radiation therapy (SIRT) with Yttrium-90

          -  Prior biliary diversion surgery

          -  Previous liver resection other than wedge resection.

          -  Pregnant patients and nursing mothers will be excluded because of the unknown effects
             of this therapy on the fetus or nursing infants.

          -  Patients taking immunosuppressive drugs or requiring ongoing chronic anticoagulation
             will not be eligible.

          -  Patients with active bacterial infections with systemic manifestations (malaise,
             fever, leucocytosis) are not eligible until completion of appropriate therapy.

          -  Patients with severe allergic reactions to iodine contrast which cannot be controlled
             by premedication with antihistamines and steroids are not eligible as a hepatic
             angiogram is needed for this procedure.

          -  Patients with a known prior hypersensitivity reaction or other contraindication to
             irinotecan will be excluded.

          -  Patients taking phenytoin, phenobarbital, carbamazepine, rifampin, rifabutin, St. John
             s Wort, or other CYP3A inducers or inhibitors are not eligible for this study.

          -  Patients are prohibited from receiving other experimental agents/adjuvant treatments
             during the study.

          -  Patients with more than one active primary malignancy, except for basal cell carcinoma
             or superficial bladder neoplasia, are to be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot B Levy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health Clinical Center (CC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Gh√©mard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8.</citation>
    <PMID>15383792</PMID>
  </reference>
  <reference>
    <citation>Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol. 2003;14 Suppl 2:ii13-6. Review.</citation>
    <PMID>12810452</PMID>
  </reference>
  <reference>
    <citation>Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 2006 Sep-Oct;26(5B):3793-5.</citation>
    <PMID>17094403</PMID>
  </reference>
  <verification_date>November 3, 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <keyword>Chemoembolization</keyword>
  <keyword>Hepatic Metastases</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Drug Eluding Beads</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>Hepatic Cancer</keyword>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

